Stocks making the biggest moves midday: Palo Alto Networks, Fervo Energy, Chevron, Apple & more
Midday trading saw declines in housing and AI infrastructure stocks, with ITB, Builders FirstSource, and Lumentum dropping. Moderna rose 5% on positive cancer vaccine trial results. Palo Alto Networks fell over 5% ahead of earnings. Apple gained 3% as John Ternus became CEO. Fervo Energy surged 25% after a major power deal with Google. Chipmakers fell with SMH down 2%. Energy stocks rose with XLE up 1%. Novartis gained 6% on positive MS drug trial data. Duolingo rose 5% after an analyst upgrade.
How this was made
The 30-second read
Why it matters
The article provides a snapshot of sector‑wide risk sentiment and isolated company catalysts that could influence short‑term trading decisions.
Market read
Highlights divergent moves across sectors, useful for traders seeking quick entry points based on fresh catalysts.
What to watch
Fervo Energy's private status limits immediate tradability, but its Google contract signals growing institutional interest in geothermal power.
Background
Midday market roundup highlighting the biggest price moves and associated news items.
Ticker impact
Palo Alto Networks slid >5% ahead of its earnings report scheduled after the bell.
Potential further downside if earnings miss expectations.
Analysts expect EPS of $0.98; any miss could trigger additional selling.
Apple shares jumped 3% as John Ternus became CEO and Tim Cook moved to executive chairman.
Short‑term upside may continue on the leadership news.
Market views the change as a smooth succession.
Chevron advanced about 1% as energy stocks rose with higher oil prices amid Middle‑East tensions.
Further gains possible if oil stays elevated.
Move is driven by broader commodity dynamics, not company‑specific news.
Moderna rose 5% after a cancer vaccine co‑developed with Merck showed positive early data in a late‑stage trial.
Expect continued upside if data are confirmed.
Phase‑III results are material for future revenue.
Novartis shares gained 6% on positive Phase‑III data for its multiple‑sclerosis drug remibrutinib.
Potential further rally on regulatory filing expectations.
MS market is sizable; efficacy data are compelling.
Duolingo rose 5% after Evercore ISI upgraded it to outperform.
Short‑term upside likely; monitor earnings for confirmation.
Upgrade reflects strong user metrics but lacks a concrete catalyst.
Medtronic gained 2% after raising its fiscal 2027 earnings outlook to $5.94‑$6 per share.
May see modest upside ahead of the fiscal year.
Guidance improvement is modest; market reaction may be limited.
Market effects
AI‑related hardware and cybersecurity stocks faced pressure, indicating short‑term risk aversion in tech.
U.S. equities showed mixed moves; energy and biotech outperformed while AI hardware lagged.
Oil price rise and biotech trial news had cross‑border relevance, affecting global commodity and pharma sentiment.
Counterpoint
The sell‑off in AI hardware may be overdone; a rebound could occur if risk appetite returns.
Key entities
- companyPalo Alto Networks
Cybersecurity firm awaiting earnings.
- companyApple
Consumer tech leader with leadership change.
- companyModerna
Biotech firm with positive cancer vaccine data.
